Report Id: PBDTM717
Bleeding Disorders Treatment Market By Drug Class Analysis (Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants); By Type Analysis (Hemophilia A, Hemophilia B, Von Willebrand Disease) and By Regional Analysis – Global Forecast by 2023-2028
The Global Bleeding Disorders Treatment Market is expected to be around US$ 22.90 Billion by 2028 at a CAGR of 8% in the given forecast period.
COVID-19 Impact Analysis Report
"Get Latest Updated Reports as per the COVID-19 Impact"
Infopedia: Access Our All Reports Online at Affordable Price
CLICK HERENorth America
8
South America
4
Europe
6
APAC
9
Others
5
MARKET SNAPSHOT
Major Players
- hire Plc
- Bayer AG
- Biogen Inc
- CSL Behring
- Novo Nordisk
Study period:
Fastest Growing Market:
2023-2028
APAC
Base Year:
Largest Market:
2022
North America
CAGR:
8
REPORT DESCRIPTION
A bleeding disorder is a condition that changes the way your blood normally clots. The clotting process is also known as coagulation, which changes the blood from a liquid to a solid. When we are injured, our blood normally begins to clot to prevent extensive loss of blood. In some cases, certain conditions keep blood from coagulating appropriately, which can bring about overwhelming or delayed dying. Draining disarranges can cause irregular draining both outside and within the body. A few issues can definitely expand the measure of blood lost by the body. Others make draining take after under the skin or in fiery organs, for example, the brain. Typical blood thickening includes blood segments called "platelets" and the same number of as there is 20 distinctive plasma proteins in body called as blood thickening or coagulation factors. These variables collaborate with different chemicals to shape a substance called fibrin.
How Big is The Global Bleeding Disorders Treatment Market?
The Global Bleeding Disorders Treatment Market is expected to be around US$ 22.90 Billion by 2028 at a CAGR of 8% in the given forecast period.
The major driving factors of Global Bleeding Disorders Treatment Market are as follows:
- Growing R&D investment for development of hemophilia products
- Rising preference for prophylactic treatment
- Raise number of diagnosed hemophilia patients
- Increase in Biosimilars product market
- Growing in healthcare expenditure
The restraining factors of Global Bleeding Disorders Treatment Market are as follows:
- Costly of hemophilia drugs
- Local government is creating high entry conditions in developing economies
- Cut throat competition from well established companies
- Inadequate reimbursement
The Global Bleeding Disorders Treatment Market is segmented on the lines of its drug class, type and regional. Based on drug class segmentation it covers plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, fibrin sealants, others. Based on type segmentation it covers hemophilia A, hemophilia B, von willebrand disease, others. The Global Bleeding Disorders Treatment Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.
This report provides:
1) An overview of the global market for Global Bleeding Disorders Treatment Market and related technologies.
2) Analyses of global market trends, with data from 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2028.
3) Identifications of new market opportunities and targeted promotional plans for Bleeding Disorders Treatment Market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
REPORT SCOPE:
The scope of the report includes a detailed study of global and regional markets on Global Bleeding Disorders Treatment Market with the reasons given for variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include hire Plc. (earlier Baxalta) (Ireland), Bayer AG (Germany), Biogen Inc. (U.S.), CSL Behring (U.S.), Novo Nordisk (Denmark), Pfizer Inc. (U.S.), and Grifols SA (Spain).Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.
The Global Bleeding Disorders Treatment Market has been segmented as below:
By Drug Class Analysis:
- Plasma-derived Coagulation Factor Concentrates
- Factor VIII
- Factor IX
- Factor for Von Willebrand Disease
- Activated Prothrombin Complex Concentrate
- Recombinant Coagulation Factor Concentrates
- Factor VIII
- Factor for Von Willebrand Disease
- Factor IX
- Desmopressin
- Antifibrinolytics
- Fibrin Sealants
- Others
By Type Analysis:
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Others
By Regional Analysis:
- North America
- Europe
- Asia-Pacific
- Rest of the World
Reasons to Buy this Report:
1) Obtain the most up to date information available on all Bleeding Disorders Treatment Market.
2) Identify growth segments and opportunities in the industry.
3) Facilitate decision making on the basis of strong historic and forecast of Global Bleeding Disorders Treatment Market data.
4) Assess your competitor’s refining portfolio and its evolution.
Customization:
We can offer you custom research reports as per client’s special requirements.
Below are our New Reports :-
1 INTRODUCTION
1.1 Key Take Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
2 Research Methodology
2.1 Introduction
2.2 Secondary Data
2.2.1 Key Data from Secondary Sources
2.3 Primary Data
2.3.1 Breakdown of Primaries
2.3.2 Key Data from Primary Sources
2.3.3 Assumptions
2.4 Market Size Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Market Breakdown and Data Triangulation
3 Executive Summary
3.1 Introduction
3.2 Market Dynamics
3.3 Market Estimation
4 Market Dynamics
4.1 Market Drivers
4.1.1 Rising R&D Investment for Development of Hemophilia Products
4.1.2 Increasing Preference for Prophylactic Treatment
4.1.3 Increasing Number of Diagnosed Hemophilia Patients
4.1.4 Increasing Healthcare Expenditure
4.2 Market Restraints
4.2.1 High Cost of Hemophilia Drugs
4.2.2 Insufficient Reimbursement
4.3 Market Opportunities
4.3.1 Local Partnerships in Pharma-emerging Countries
4.3.2 Rising Disposable Income and Improving Healthcare Infrastructure in Developing Nations
4.3.3 Growing Biosimilar Products Market
4.4 Market Threats
4.4.1 High Entry Barriers Created By Local Government in Certain Countries
4.4.2 Low Switch Rate for Hemophilia Products
4.4.3 High Competition from Established Players
5 Global Bleeding Disorders Treatment Market, By Type
5.1 Introduction
5.2 Hemophilia A
5.3 Hemophilia B
5.4 Von Willebrand Disease (vWD)
5.5 Others
6 Global Bleeding Disorders Treatment Market, By Drug Class
6.1 Introduction
6.2 Plasma Derived Coagulation Factor Concentrates Market
6.3 Global Recombinant Coagulation Factor Concentrate Market
6.4 Global Others Bleeding Disorders Treatment Market
7 Global Bleeding Disorders Treatment Market, By Geography
7.1 Introduction
7.2 North America
7.3 Europe
7.4 Asia-Pacific
7.5 Rest of the World (RoW)
8 Competitive Landscape
8.1 Market Share Analysis, By Key Players
8.2 Key Growth Strategies, 2015 -2018
8.3 Key Growth Strategies: New Product Approval/ Launch, 2015 -2018
8.4 Key Growth Strategies: Agreements, 2015 -2018
8.5 Key Growth Strategies: M&A, 2015 -2018
8.6 Key Growth Strategies: Other Strategies, 2015 -2018
9 Company Profiles
9.1 Baxalta (Now Shire)
9.2 Bayer Pharmaceuticals
9.3 Novo Nordisk A/S
9.4 Pfizer Inc.
9.5 Biogen Idec
9.6 CSL Behring
9.7 Grifols
9.8 Octapharma
The Global Bleeding Disorders Treatment Market has been segmented as below:
By Drug Class Analysis:
- Plasma-derived Coagulation Factor Concentrates
- Factor VIII
- Factor IX
- Factor for Von Willebrand Disease
- Activated Prothrombin Complex Concentrate
- Recombinant Coagulation Factor Concentrates
- Factor VIII
- Factor for Von Willebrand Disease
- Factor IX
- Desmopressin
- Antifibrinolytics
- Fibrin Sealants
- Others
By Type Analysis:
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Others
By Regional Analysis:
- North America
- Europe
- Asia-Pacific
- Rest of the World
Got a question? We've got answers. If you have some other questions, see our support center.
What is the predicted growth rate of Bleeding Disorders Treatment Market?
The market is expected to grow at a CAGR of 8% during the study period (2023-2028)
How big is the Bleeding Disorders Treatment Market value?
The Global Bleeding Disorders Treatment Market is expected to be around US$ 22.90 Billion by 2028
What is the segment’s covered for the Bleeding Disorders Treatment Market?
The segment included in the Bleeding Disorders Treatment Market is Drug Class, Type and region.
Who are the major key vendors in the Bleeding Disorders Treatment Market?
Some key players operating in the Bleeding Disorders Treatment Market include hire Plc. (earlier Baxalta) (Ireland), Bayer AG (Germany), Biogen Inc. (U.S.), CSL Behring (U.S.), Novo Nordisk (Denmark), Pfizer Inc. (U.S.), and Grifols SA (Spain)
What are the different forms of the report available?
We can offer several formats of the market research reports including,
• PDF
• PPT
• Spreadsheet/ Workbook
© 2020 COPYRIGHT : MARKET RESEARCH ENGINE